本季度信息
根据公司公告，华润医药下属子公司东阿阿胶在截至2026年9月30日止九个月内，实现营收49.40亿元（人民币，下同），较去年同期的47.66亿元增长3.65%。同期，经调整后净利润为13.28亿元，较上年同期的12.77亿元增长4.00%。公告显示，东阿阿胶财务数据依据中国公认会计准则编制，尚未经审阅或审计。
期内，东阿阿胶的现金及现金等价物净额由上年同期的5.10亿元增加额转为7.63亿元净减少，期末现金及现金等价物余额为26.43亿元。公司同期资产总额为124.24亿元，负债总额为25.58亿元，所有者权益合计为98.65亿元。公告提醒，本次公布财务数据仅反映东阿阿胶经营与财务指标，尚不足以全面体现华润医药集团整体经营表现。
业务分项
东阿阿胶为华润医药集团的重要子公司。从公告披露的财报数据看，东阿阿胶在报告期内实现了营收和净利润的稳定增长，但同期现金及现金等价物由正转负。集团方面指出，相关数据仍需经过专业机构审阅或审计。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.